Type 2 diabetes treatment: Novo Nordisk set to file with the FDA
Diabetes innovation is evidently high on the agenda - a story about how Novo Nordisk expects to file for regulatory approval of its once-weekly insulin icodec injection in the US, the EU and China in the first half of 2023 was the fourth highest in terms of readership traffic rankings for October.
And the Danish pharma giant says the approach represents a new treatment paradigm for type 2 diabetes: “We believe that our investigational weekly insulin icodec has the potential to offer a new standard of care in this space.”
Photo credit: GettyImages/martin-dm
